Top

Published in:

01-06-2007 | Original Article

Individual Vγ2-Jγ1.2+ T cells respond to both isopentenyl pyrophosphate and Daudi cell stimulation: generating tumor effectors with low molecular weight phosphoantigens

Authors: Andrew M. Hebbeler, Cristiana Cairo, Jean Saville Cummings, C. David Pauza

Published in: Cancer Immunology, Immunotherapy | Issue 6/2007

Abstract

Human Vγ2Vδ2 T cells exhibit T cell receptor-dependent, MHC-unrestricted recognition of antigen and play important roles in tumor and pathogen immunity. To characterize antigen recognition by the Vγ2Vδ2 TCR, we used the combined approach of spectratyping and CDR3 sequence analysis that measures changes in the TCR repertoire before and after stimulation with a phosphoantigen (isopentenyl pyrophosphate) or an irradiated tumor cell line (Daudi B lymphoma). Here we describe common Vγ2 chains that are substantially involved in the response to both phosphoantigens and tumor cells. The recognition properties of common Vγ2 chains explains the observation that Vγ2Vδ2 T cells expanded by phosphoantigen stimulation specifically recognize and kill some but not all tumor cell lines. Our studies further justify efforts to stimulate tumor immunity by administering low molecular weight phosphoantigens and boosting the frequency and tumor effector functions of circulating Vγ2Vδ2 T cells.

Boismenu R, Havran WL (1997) An innate view of gamma delta T cells. Curr Opin Immunol 9:57–63PubMedCrossRef

Brenner MB, McLean J, Scheft H, Riberdy J, Ang SL, Seidman JG, Devlin P, Krangel MS (1987) Two forms of the T-cell receptor gamma protein found on peripheral blood cytotoxic T lymphocytes. Nature 325:689–694PubMedCrossRef

Bukowski JF, Morita CT, Brenner M (1999) Human gamma delta T cells recognize alkylamines derived from microbes, edible plants, and tea: implications for innate immunity. Immunity 11:57–65PubMedCrossRef

Burns J, Lobo S, Bartholomew B (1996) Requirement for CD4+ T cells in the gammadelta T cell proliferative response to Daudi Burkitt’s lymphoma. Cell Immunol 174:19–24PubMedCrossRef

Caccamo N, Dieli F, Wesch D, Jomaa H, Eberl M (2006) Sex-specific phenotypical and functional differences in peripheral human Vgamma9/Vdelta2 T cells. J Leukoc Biol 79:663–666PubMedCrossRef

Cairo C, Propp N, Hebbeler AM, Colizzi V, Pauza CD (2005) The Vgamma2/Vdelta2 T-cell repertoire in Macaca fascicularis: functional responses to phosphoantigen stimulation by the Vgamma2/Jgamma1.2 subset. Immunology 115:197–205PubMedCrossRef

Casorati G, De Libero G, Lanzavecchia A, Migone N (1989) Molecular analysis of human gamma/delta+ clones from thymus and peripheral blood. J Exp Med 170:1521–1535PubMedCrossRef

Cipriani B, Borsellino G, Poccia F, Placido R, Tramonti D, Bach S, Battistini L, Brosnan CF (2000) Activation of C-C beta-chemokines in human peripheral blood gammadelta T cells by isopentenyl pyrophosphate and regulation by cytokines. Blood 95:39–47PubMed

Constant P, Davodeau F, Peyrat MA, Poquet Y, Puzo G, Bonneville M, Fournie JJ (1994) Stimulation of human gamma delta T cells by nonpeptidic mycobacterial ligands. Science 264:267–270PubMedCrossRef

10.

Corvaisier M, Moreau-Aubry A, Diez E, Bennouna J, Mosnier JF, Scotet E, Bonneville M, Jotereau F (2005) V gamma 9V delta 2 T cell response to colon carcinoma cells. J Immunol 175:5481–5488PubMed

11.

Das H, Wang L, Kamath A, Bukowski JF (2001) Vgamma2Vdelta2 T-cell receptor-mediated recognition of aminobisphosphonates. Blood 98:1616–1618PubMedCrossRef

12.

Davodeau F, Peyrat MA, Hallet MM, Gaschet J, Houde I, Vivien R, Vie H, Bonneville M (1993) Close correlation between Daudi and mycobacterial antigen recognition by human gamma delta T cells and expression of V9JPC1 gamma/V2DJC delta-encoded T cell receptors. J Immunol 151:1214–1223PubMed

13.

De Libero G, Casorati G, Giachino C, Carbonara C, Migone N, Matzinger P, Lanzavecchia A (1991) Selection by two powerful antigens may account for the presence of the major population of human peripheral gamma/delta T cells. J Exp Med 173:1311–1322PubMedCrossRef

14.

Deetz C, Hebbeler A, Propp N, Cairo C, Tikhonov I, Pauza C (2006) Interferon-gamma secretion by human Vg2Vd2 T cells after stimulation with antibody against the T cell receptor plus the toll-like receptor 2 agonist, Pam3Cys. Infect Immun 74:4505–4511PubMedCrossRef

15.

Devilder MC, Maillet S, Bouyge-Moreau I, Donnadieu E, Bonneville M, Scotet E (2006) Potentiation of antigen-stimulated V gamma 9V delta 2 T cell cytokine production by immature dendritic cells (DC) and reciprocal effect on DC maturation. J Immunol 176:1386–1393PubMed

16.

Eberl M, Hintz M, Reichenberg A, Kollas AK, Wiesner J, Jomaa H (2003) Microbial isoprenoid biosynthesis and human gammadelta T cell activation. FEBS Lett 544:4–10PubMedCrossRef

17.

Enders PJ, Yin C, Martini F, Evans PS, Propp N, Poccia F, Pauza CD (2003) HIV-mediated gammadelta T cell depletion is specific for Vgamma2+ cells expressing the Jgamma1.2 segment. AIDS Res Hum Retroviruses 19:21–29PubMedCrossRef

18.

Evans PS, Enders PJ, Yin C, Ruckwardt T, Malkovsky M, Pauza CD (2001) In vitro stimulation with a non-peptidic alkylphosphate antigen expands cells expressing the Vγ2-Jγ1.2/Vδ2 T cell receptors. Immunology 104:19–27PubMedCrossRef

19.

Fazilleau N, Cabaniols JP, Lemaitre F, Motta I, Kourilsky P, Kanellopoulos JM (2005) Valpha and Vbeta public repertoires are highly conserved in terminal deoxynucleotidyl transferase-deficient mice. J Immunol 174:345–355PubMed

20.

Ferrarini M, Ferrero E, Dagna L, Poggi A, Zocchi MR (2002) Human gammadelta T cells: a nonredundant system in the immune-surveillance against cancer. Trends Immunol 23:14–18PubMedCrossRef

21.

Fisch P, Malkovsky M, Braakman E, Sturm E, Bolhuis RL, Prieve A, Sosman JA, Lam VA, Sondel PM (1990) Gamma/delta T cell clones and natural killer cell clones mediate distinct patterns of non-major histocompatibility complex-restricted cytolysis. J Exp Med 171:1567–1579PubMedCrossRef

22.

Fisch P, Malkovsky M, Kovats S, Sturm E, Braakman E, Klein BS, Voss SD, Morrissey LW, DeMars R, Welch WJ, Bolhuis RLH, Sondel PM (1990) Recognition by human V gamma 9/V delta 2 T cells of a GroEL homolog on Daudi Burkitt’s lymphoma cells. Science 250:1269–1273PubMedCrossRef

23.

Gioia C, Agrati C, Casetti R, Cairo C, Borsellino G, Battistini L, Mancino G, Goletti D, Colizzi V, Pucillo LP, Poccia F (2002) Lack of CD27-CD45RA-V gamma 9V delta 2+ T cell effectors in immunocompromised hosts and during active pulmonary tuberculosis. J Immunol 168:1484–1489PubMed

24.

Halary F, Fournie JJ, Bonneville M (1999) Activation and control of self-reactive gammadelta T cells. Microbes Infect 1:247–253PubMedCrossRef

25.

Kaur I, de Jong J, Schell K, Hank J, Fisch P, Sondel PM (1994) Human peripheral gamma delta T cells are stimulated by Daudi Burkitt’s lymphoma and not by any other Burkitt’s lymphoma tested. Cell Immunol 156:54–61PubMedCrossRef

26.

Kobayashi H, Tanaka Y, Yagi J, Toma H, Uchiyama T (2001) Gamma/delta T cells provide innate immunity against renal cell carcinoma. Cancer Immunol Immunother 50:115–124PubMedCrossRef

27.

Kunzmann V, Feurle J, Weissinger F, Tony H, Wilhelm M (2000) Stimulation of gammadelta T cells by aminobisphosphonates and induction of antiplasma cell activity in multiple myeloma. Blood 96:384–392PubMed

28.

Laad AD, Thomas ML, Fakih AR, Chiplunkar SV (1999) Human gamma delta T cells recognize heat shock protein-60 on oral tumor cells. Int J Cancer 80:709–714PubMedCrossRef

29.

Lang F, Peyrat MA, Constant P, Davodeau F, David-Ameline J, Poquet Y, Vie H, Fournie JJ, Bonneville M (1995) Early activation of human V gamma 9V delta 2 T cell broad cytotoxicity and TNF production by nonpeptidic mycobacterial ligands. J Immunol 154:5986–5994PubMed

30.

Malkovska V, Cigel F, Storer BE (1994) Human T cells in hu-PBL-SCID mice proliferate in response to Daudi lymphoma and confer anti-tumour immunity. Clin Exp Immunol 96:158–165PubMedCrossRef

31.

Miyagawa F, Tanaka Y, Yamashita S, Minato N (2001) Essential requirement of antigen presentation by monocyte lineage cells for the activation of primary human gamma delta T cells by aminobisphosphonate antigen. J Immunol 166:5508–5514PubMed

32.

Neri S, Mariani E, Meneghetti A, Cattini L, Facchini A (2001) Calcein-acetyoxymethyl cytotoxicity assay: standardization of a method allowing additional analyses on recovered effector cells and supernatants. Clin Diagn Lab Immunol 8:1131–1135PubMedCrossRef

33.

Nikolich-Zugich J, Slifka MK, Messaoudi I (2004) The many important facets of T-cell repertoire diversity. Nat Rev Immunol 4:123–132PubMedCrossRef

34.

Panchamoorthy G, McLean J, Modlin RL, MOrita CT, Ishikawa S, Brenner MB, Band H (1991) A predominance of the T cell receptor Vgamma2/V delta2 subset in human mycobacterial-responsive T cells suggests germline gene encoded recognition. J Immunol 147:3360–3369PubMed

35.

Poccia F, Malkovsky M, Pollak A, Colizzi V, Sireci G, Salerno A, Dieli F (1999) In vivo gammadelta T cell priming to mycobacterial antigens by primary Mycobacterium tuberculosis infection and exposure to nonpeptidic ligands. Mol Med 5:471–476PubMed

36.

Rakasz EG, McDougall A, Zayas M, Helgeland JL, Ruckwardt T, Hatfield G, Dykhuizen M, Mitchen JL, Evans PS, Pauza CD (2000) Gammadelta T cell receptor repertoire in blood and colonic mucosa of Rhesus macaques. J Med Primatol 29:387–396PubMedCrossRef

37.

Scotet E, Martinez LO, Grant E, Barbaras R, Jeno P, Guiraud M, Monsarrat B, Saulquin X, Maillet S, Esteve JP, Lopez F, Perret B, Collet X, Bonneville M, Champagne E (2005) Tumor recognition following Vgamma9Vdelta2 T cell receptor interactions with a surface F1-ATPase-related structure and apolipoprotein A-I. Immunity 22:71–80PubMedCrossRef

38.

Sicard H, Al Saati T, Delsol G, Fournie JJ (2001) Synthetic phosphoantigens enhance human Vgamma9Vdelta2 T lymphocytes killing of non-Hodgkin’s B lymphoma. Mol Med 7:711–722PubMed

39.

Thomas ML, Samant UC, Deshpande RK, Chiplunkar SV (2000) gammadelta T cells lyse autologous and allogenic oesophageal tumours: involvement of heat-shock proteins in the tumour cell lysis. Cancer Immunol Immunother 48:653–659PubMedCrossRef

40.

Tikhonov I, Deetz CO, Paca R, Berg S, Lukyanenko V, Lim JK, Pauza CD (2006) Human V{gamma}2V{delta}2 T cells contain cytoplasmic RANTES. Int Immunol 18:1243–1251PubMedCrossRef

41.

Wilhelm M, Kunzmann V, Eckstein S, Reimer P, Weissinger F, Ruediger T, Tony HP (2003) Gammadelta T cells for immune therapy of patients with lymphoid malignancies. Blood 102:200–206PubMedCrossRef

Title: Individual Vγ2-Jγ1.2+ T cells respond to both isopentenyl pyrophosphate and Daudi cell stimulation: generating tumor effectors with low molecular weight phosphoantigens
Authors: Andrew M. Hebbeler
Cristiana Cairo
Jean Saville Cummings
C. David Pauza
Publication date: 01-06-2007
Publisher: Springer-Verlag
Published in: Cancer Immunology, Immunotherapy / Issue 6/2007
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI: https://doi.org/10.1007/s00262-006-0235-6

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 6/2007

T cells remaining after intensive chemotherapy for acute myelogenous leukemia show a broad cytokine release profile including high levels of interferon-γ that can be further increased by a novel protein kinase C agonist PEP005

Imatinib impairs CD8+ T lymphocytes specifically directed against the leukemia-associated antigen RHAMM/CD168 in vitro

Efficacy of adjuvant immunochemotherapy with polysaccharide K for patients with curative resections of gastric cancer

Adjuvant properties of listeriolysin O protein in a DNA vaccination strategy

A new tumor-specific antigen encoded by MAGE-C2 and presented to cytolytic T lymphocytes by HLA-B44

Molecular and immunological evaluation of the expression of cancer/testis gene products in human colorectal cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer